Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MELBOURNE, Australia and NEW YORK, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, announced that the...
-
NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) announced today that the independent Data Monitoring Committee (DMC) overseeing the Phase 3 trial of Revascor...
-
NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that its Phase 3 trial of Revascor for advanced chronic heart failure has surpassed the number...
-
MELBOURNE, Australia and NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported operational highlights and financial results for the first quarter ended...
-
NEW YORK and MELBOURNE, Australia, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst...
-
MELBOURNE, Australia and NEW YORK and BASEL, Switzerland, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Mesoblast (ASX:MSB; Nasdaq:MESO) and Lonza (SWX: LONN) announced today that they have entered into an...
-
NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB), leader in cellular medicines for inflammatory diseases, announced today that it has successfully completed a...
-
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will provide a corporate update during an...
-
AACHEN, Germany, and MELBOURNE, Australia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Grünenthal, a global leader in pain management, and Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a world leader in...
-
NEW YORK and MELBOURNE, Australia, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today reported strong operational progress and financial highlights for the fourth...